China's medical product administrator approved Guangxi Wuzhou Zhongheng's (SHA:600252) nicorandil tablets and ketorolac tromethamine injection, according to a Thursday filing with the Shanghai bourse.
The nicorandil tablets are indicated for angina pectoris or chest pain, while the ketorolac tromethamine injection is indicated for post-operative pain relief, the filing said.
Shares fell 1% during afternoon trading on Thursday.